Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of “Hold” by Brokerages

Revance Therapeutics, Inc. (NASDAQ:RVNC) has received a consensus recommendation of “Hold” from the nine research firms that are currently covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $8.39.

A number of research analysts have recently weighed in on RVNC shares. Barclays cut their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Mizuho reduced their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Finally, StockNews.com initiated coverage on Revance Therapeutics in a report on Monday, March 10th. They issued a “hold” rating for the company.

Institutional Investors Weigh In On Revance Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new position in Revance Therapeutics during the 3rd quarter valued at $108,000. Accredited Investors Inc. bought a new position in shares of Revance Therapeutics during the 3rd quarter worth about $67,000. LMR Partners LLP acquired a new position in shares of Revance Therapeutics during the third quarter valued at about $11,648,000. Alpine Associates Management Inc. bought a new stake in shares of Revance Therapeutics in the third quarter valued at about $21,605,000. Finally, Intech Investment Management LLC acquired a new stake in Revance Therapeutics during the third quarter worth about $231,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Price Performance

NASDAQ RVNC opened at $3.65 on Monday. The stock has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.56. The company has a 50 day moving average price of $3.59 and a two-hundred day moving average price of $4.33.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.